Case 1 Presentation (cont): mHSPC
Evan Y. Yu, MD, discusses how the presentation of a patient with metastatic hormone-sensitive prostate cancer (mHSPC) involves evaluating key clinical features such as disease extent, symptoms, and performance status to guide treatment decisions and the selection of appropriate systemic therapies.
Video content above is prompted by the following:
- Please discuss how you approach individualized first-line systemic therapy selection for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
- Please offer perspectives on pros/cons of current options for first-line therapy.
- What factors do you consider during treatment decision-making (eg, use of chemotherapy-sparing regimens, ARPI selection, triplet versus doublet combination systemic therapy)?
Recent Videos
Related Content
